Manufacturers present phase 3 study data for omidubicel in patients with haematologic malignancies

This cell therapy treatment showed faster hematopoietic recovery, fewer bacterial and viral infections and fewer days in hospital versus comparator. Diseases investigated included acute lymphoblastic and myelogenous leukaemia’s, chronic myelogenous leukaemia and lymphoma.

Biospace Inc.